UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 202

Sortiert nach

Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib

Clinical and experimental dermatology, 2022-04, Vol.47 (4), p.748-750

2022

Volltextzugriff (PDF)

Assessing the safety of biologic agents in patients with rheumatoid arthritis

Rheumatology (Oxford, England), 2012-07, Vol.51 Suppl 5 (suppl 5), p.v38-v47

Rubbert-Roth, Andrea

2012

Volltextzugriff (PDF)

Pulmonary involvement in rheumatoid arthritis

Zeitschrift für Rheumatologie, 2019-04, Vol.78 (3), p.228-235

2019

Volltextzugriff (PDF)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

Annals of the rheumatic diseases, 2011-05, Vol.70 (5), p.755-759

2011

Volltextzugriff (PDF)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.979-984

2015

Volltextzugriff (PDF)

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.39-46

2011

Volltextzugriff (PDF)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

Annals of the Rheumatic Diseases, 2013-04, Vol.72 (suppl 2), p.ii2

2013

Volltextzugriff (PDF)

S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs

Zeitschrift für Rheumatologie, 2018-08, Vol.77 (Suppl 2), p.35-53

2018

Volltextzugriff (PDF)

Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic

Zeitschrift für Rheumatologie, 2015-06, Vol.74 (5), p.406-413

Rubbert-Roth, A

2015

Volltextzugriff (PDF)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

The New England journal of medicine, 2015-12, Vol.373 (26), p.2534-2548

2015

Volltextzugriff (PDF)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

The Lancet (British edition), 2018-06, Vol.391 (10136), p.2213-2224

2018

Volltextzugriff (PDF)

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

The Lancet (British edition), 2018-12, Vol.392 (10163), p.2441-2451

2018

Volltextzugriff (PDF)

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

Multiple sclerosis, 2009-02, Vol.15 (2), p.189-192

2009

Volltextzugriff (PDF)

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

The New England journal of medicine, 2015-10, Vol.373 (14), p.1329-1339

2015

Volltextzugriff (PDF)

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

The Lancet (British edition), 2013, Vol.381 (9877), p.1541-1550

2013

Volltextzugriff (PDF)

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

The Lancet (British edition), 2008-03, Vol.371 (9617), p.987-997

2008

Volltextzugriff (PDF)

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs

Rheumatology (Oxford, England), 2012-07, Vol.51 Suppl 5 (suppl 5), p.v12-v21

2012

Volltextzugriff (PDF)

Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa

Zeitschrift für Rheumatologie, 2012-02, Vol.71 (2), p.119

Rubbert-Roth, A

2012

Volltextzugriff (PDF)

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2023-09, Vol.75 (9), p.1608-1618

2023

Volltextzugriff (PDF)

FRI0199 Rituximab in Combination with Leflunomide: Results from A Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study)

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.502

2016

Volltextzugriff (PDF)

FRI0173 Gastrointestinal perforations with certolizumab PEGOL

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.370-370

2013

Volltextzugriff (PDF)

SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.721-721

2015

Volltextzugriff (PDF)

OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.78-78

2015

Volltextzugriff (PDF)

SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.723-724

2015

Volltextzugriff (PDF)

Recommendations on the use of rituximab for ANCA-associated vasculitis

Zeitschrift für Rheumatologie, 2014-04, Vol.73 (3), p.287-289

2014

Volltextzugriff (PDF)

1 – 25 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(185)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Rheumatology
(113)
Science & Technology
(112)
Life Sciences & Biomedicine
(110)
Humans
(97)
Rheumatoid Arthritis
(61)
Arthritis, Rheumatoid - Drug Therapy
(59)
Treatment Outcome
(46)
Antirheumatic Agents - Therapeutic Use
(43)
Female
(42)
Male
(42)
Adult
(36)
Middle Aged
(36)
Immunology
(33)
Medicine
(32)
Medicine & Public Health
(31)
Internal Medicine
(30)
Patients
(28)
Antirheumatic Agents - Adverse Effects
(27)
Orthopedics
(27)
Tumor Necrosis Factor-Tnf
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib

Assessing the safety of biologic agents in patients with rheumatoid arthritis

Pulmonary involvement in rheumatoid arthritis

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs

Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs

Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

FRI0199 Rituximab in Combination with Leflunomide: Results from A Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study)

FRI0173 Gastrointestinal perforations with certolizumab PEGOL

SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI)

OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study

SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study

Recommendations on the use of rituximab for ANCA-associated vasculitis

Suchergebnisse filtern